What is Zacks Small Cap’s Forecast for ABEO Q3 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Stock analysts at Zacks Small Cap issued their Q3 2025 EPS estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings per share of ($0.34) for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.40 EPS.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.19.

A number of other research analysts also recently weighed in on ABEO. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday. Finally, Oppenheimer started coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $4.99 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45. The stock has a market capitalization of $216.92 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. The business’s fifty day moving average price is $5.43 and its 200-day moving average price is $5.82.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ABEO. Jane Street Group LLC bought a new stake in Abeona Therapeutics during the 3rd quarter worth approximately $84,000. JPMorgan Chase & Co. increased its stake in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 28,606 shares in the last quarter. Western Standard LLC raised its position in shares of Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the period. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics during the 3rd quarter valued at $151,000. Finally, XTX Topco Ltd purchased a new position in shares of Abeona Therapeutics during the 3rd quarter valued at $160,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.